Associated Papers
Driver gene alterations profiling of Chinese non-small cell lung cancer and the effects of co-occurring alterations on immunotherapy.
Sun S et al.
Cancer Medicine, 2021
34599863 (PubMed )
Supplement: CAM4-10-7360-s002.xlsx › S2
EGFR mutation status in a series of Turkish non-small cell lung cancer patients.
Calibasi-Kocal G et al.
Biomedical Reports, 2020
Spectrum of EGFR aberrations and potential clinical implications: insights from integrative pan-cancer analysis.
Liu H et al.
Cancer Communications (london, England), 2020
32067422 (PubMed )
Supplement: CAC2-40-43-s001.xlsx › Table_S1
Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S et al.
Genome Medicine, 2018
30053901 (PubMed )
Supplement: 13073_2018_564_MOESM2_ESM.xlsx › 13
A novel point mutation in exon 20 of EGFR showed sensitivity to erlotinib.
Xing K et al.
Medical Oncology (northwood, London, England), 2014
Epidemiology of doublet/multiplet mutations in lung cancers: evidence that a subset arises by chronocoordinate events.
Chen Z et al.
Plos One, 2008
19005564 (PubMed )
Supplement: pone.0003714.s003.xls › Table_S-1
Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma.
Sonobe M et al.
British Journal of Cancer, 2005
Select a paper to view details